Abbvie Inc.

Roopal B Thakkar

Ahmed A Othman

Mohamed-Eslam F Mohamed

Ben Klünder

Thomas B Borchardt

Peter T Mayer

Jayanthy Jayanth

Patrick J Marroum

Aileen L Pangan

Mathew M Mulhern

Fredrik Lars Nordstrom

Ana Paula Machado De Lacerda

Wen Zhou

Steven Jungerwirth

Anne M Robinson

Ayman D Allian

Ahmed Othman

Ben Klunder

Mohamed-Eslam Mohamed

Ahmad Y Sheikh

The present disclosure is directed to methods for treating Crohn's disease, and in particular, to methods for inducing clinical remission and/or endoscopic improvement of Crohn's disease, using a JAK1 inhibitor. In certain embodiments, the patient is administered an induction dose of the JAK1 inhibitor to induce clinical remission and/or endoscopic improvement of the Crohn's disease, followed by administration of at least one maintenance dose of the JAK1 inhibitor thereafter. In other embodiments, the present disclosure is directed to methods for treating ulcerative colitis using a JAK1 inhibitor.

Methods of treating crohn's disease and ulcerative colitis

Growing community of inventors

Lake Forest, IL, United States of America

Roopal B Thakkar